28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
The CITA GO-ON Study, as a part of the World-Wide FINGERS network, is designed to validate the efficacy of a multidomain lifestyle intervention for dementia prevention and contribute valuable data to inform public health strategies fostering healthy, active aging. 3 key findings →
Design: randomized controlled trial Participants: 1,051 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The COVID-19 pandemic forced adult day services (ADS) to close and abruptly end in-person services to clients. 5 key findings →
Design: randomized controlled trial Participants: 19 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In the first of five phases in the evolution of beta-amyloidosis Abeta deposits are found exclusively in the neocortex. 5 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our results provide evidence of the potential of Souvenaid™ therapy for the treatment of behavioral disturbances and social cognition skills in FTD. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Neuro-inflammation was not reduced between the neflamapimod and placebo groups, and no change was observed in [18F]-DPA-714 PET. 5 key findings →
Design: randomized controlled trial Participants: 17 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Researchers conducted a trial to test the effect of omega 3 polyunsaturated fatty acid supplementation and a multidomain intervention, alone or in combination, compared with placebo, on cognitive decline in elderly adults with memory complaints. 3 key findings →
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The traditional Mediterranean diet (MedDiet), rich in minimally processed plant foods and fish, has been widely recognized to be one of the healthiest diets. 3 key findings →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source
Nilotinib is safe and achieves pharmacologically relevant cerebrospinal fluid concentrations. 4 key findings →
Design: clinical trial Participants: 37 Evidence: high
Full summary, score breakdown and related studies → Original source
The CAD106 first-in-human study demonstrated a favorable safety profile and promising antibody response. 4 key findings →
Design: open-label trial Participants: 47 Evidence: high
Full summary, score breakdown and related studies → Original source
Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. 4 key findings →
Participants: 206 Evidence: high
Full summary, score breakdown and related studies → Original source
Cognitive functioning, mood, and health-related QOL were significantly improved following a 24-week course of the acetylcholinesterase inhibitor donepezil. 5 key findings →
Design: open-label trial Participants: 35 Evidence: low
Full summary, score breakdown and related studies → Original source
In the CU, using combined plasma Aβ42/40 and p-tau217 cut-offs for eligibility yielded the lowest sample size estimates for a comprehensive multidomain cognitive composite score, whereas sample sizes were higher for all other inclusion criteria based on single biomarkers. 5 key findings →
Participants: 225 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The primary outcome is change in plasma p-tau181 concentration between baseline and following 180 days of treatment, which will be compared between the active and placebo group. 3 key findings →
Participants: 60 Evidence: high
Full summary, score breakdown and related studies → Original source
This study aims to provide confirmatory evidence of the effect of the Korean herbal medicine, KGT, on improving cognitive function in patients with aMCI. 3 key findings →
Participants: 84 Evidence: high
Full summary, score breakdown and related studies → Original source
Although modest, the changes induced by EGb were objectively measured by the ADAS-Cog and were of sufficient magnitude to be recognized by the caregivers in the GERRI. 5 key findings →
Participants: 309 Evidence: high
Full summary, score breakdown and related studies → Original source
The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial. 2 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In this exploratory study, SB-742457 and donepezil were associated with improvements in global function. 2 key findings →
Participants: 61 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The objective of this study was to compare the effects of a multisensory stimulation environment (MSSE) and individualized music sessions on agitation, emotional and cognitive status, and dementia severity in a sample of institutionalized patients with severe dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These results indicate that trans-resveratrol has potential neuroprotective roles in the treatment of moderate to mild AD and that its mechanism may involve a reduction in the accumulation and toxicity of Aβ in the brain of patients, thereby reducing neuroinflammation. 4 key findings →
Design: case-control study Participants: 15 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A safe and effective medicine, huperzine Alpha remarkably improves the cognition, behavior, ADL,and mood of AD patients. 2 key findings →
Participants: 100 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The effects of antidepressants on mood, cognition and the daily activities of Alzheimer patients are ambiguous. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among caregivers, this small randomized controlled trial found that escitalopram use resulted in improvement in depression, resilience, burden and distress, and quality of life. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The MAXCOG intervention is effective in improving goal performance and satisfaction in clients with MCI and early dementia. 2 key findings →
Design: randomized controlled trial Participants: 55 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
These post-hoc analyses support the beneficial effects of memantine on cognition observed in a previously reported clinical trial. 4 key findings →
Design: post-hoc analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Benefit-finding is an efficacious intervention for depressive symptoms in Alzheimer caregivers, with strong effects in the medium-term post-intervention and possible moderate effects in the longer-term post-intervention. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
10 of the 1,875 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →